About this item:

439 Views | 294 Downloads

Author Notes:

Correspondence: James G. Kahn, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, California; Email: jgkahn@ucsf.edu

Authors' Contributions: Conceived and designed the experiments: JGK.

Analyzed the data: JGK and BH.

Wrote the paper: JGK, BH, EL, TC, JM, SS, MG and NM.

Brian Harris was hired by Super Models for Global Health (Dr. Kahn) to monitor the IPC in Kakamega in September 2008, and to do an analysis afterward.

This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

The other authors have no conflicts of interest to declare.

Subject:

Research Funding:

This work was funded by Vestergaard Frandsen and by the U.S. National Institute for Drug Abuse, under R01 DA15612.

Vestergaard Frandsen paid J. G. Kahn (SMGH) to conduct the analysis, write the manuscript and to travel to two meetings to present study results.

London Vestergaard Frandsen paid for T. Clasen's field visit to Kenya study site and fees for time spent on study.

Integrated HIV Testing, Malaria, and Diarrhea Prevention Campaign in Kenya: Modeled Health Impact and Cost-Effectiveness

Tools:

Journal Title:

PLoS ONE

Volume:

Volume 7, Number 2

Publisher:

, Pages 1-9

Type of Work:

Article | Final Publisher PDF

Abstract:

Background Efficiently delivered interventions to reduce HIV, malaria, and diarrhea are essential to accelerating global health efforts. A 2008 community integrated prevention campaign in Western Province, Kenya, reached 47,000 individuals over 7 days, providing HIV testing and counseling, water filters, insecticide-treated bed nets, condoms, and for HIV-infected individuals cotrimoxazole prophylaxis and referral for ongoing care. We modeled the potential cost-effectiveness of a scaled-up integrated prevention campaign. Methods We estimated averted deaths and disability-adjusted life years (DALYs) based on published data on baseline mortality and morbidity and on the protective effect of interventions, including antiretroviral therapy. We incorporate a previously estimated scaled-up campaign cost. We used published costs of medical care to estimate savings from averted illness (for all three diseases) and the added costs of initiating treatment earlier in the course of HIV disease. Results Per 1000 participants, projected reductions in cases of diarrhea, malaria, and HIV infection avert an estimated 16.3 deaths, 359 DALYs and $85,113 in medical care costs. Earlier care for HIV-infected persons adds an estimated 82 DALYs averted (to a total of 442), at a cost of $37,097 (reducing total averted costs to $48,015). Accounting for the estimated campaign cost of $32,000, the campaign saves an estimated $16,015 per 1000 participants. In multivariate sensitivity analyses, 83% of simulations result in net savings, and 93% in a cost per DALY averted of less than $20. Discussion A mass, rapidly implemented campaign for HIV testing, safe water, and malaria control appears economically attractive.

Copyright information:

© 2012 Kahn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote